AbbVie Cuts Profit Forecast on Apogee Acquisition, Stock Drops

AbbVie reported second-quarter results on Friday that surpassed analyst expectations, yet the company's decision to lower its full-year profit forecast due to its planned acquisition of Apogee Therapeutics caused its stock to decline by more than 4% in premarket trading. The pharmaceutical giant's earnings beat was overshadowed by the financial implications of the upcoming deal, which is expected to close in the near future. The revised forecast reflects the anticipated costs and dilution associated with the acquisition. Investors reacted negatively to the news, despite the strong quarterly performance. The acquisition of Apogee Therapeutics, a biotech firm, is part of AbbVie's strategy to expand its portfolio, particularly in immunology and other therapeutic areas. The stock's decline in premarket trading indicates market concerns about the deal's impact on near-term profitability. AbbVie's management has not provided further details on the acquisition's timeline or financial terms beyond the forecast adjustment. The company's shares have been volatile in recent months, influenced by both its pipeline developments and M&A activities. This development is significant for investors tracking AbbVie's financial health and strategic direction.